At Worldwide, we know an obesity program lives or dies on whether the sites understand the patients in their waiting rooms. Our obesity site alliance is selected for DEXA access, research experience and bias-trained teams, backed by 115+ combined years of obesity expertise and an early-phase engine built for investor timelines, so our partners move at the speed a Phase II readout demands.
We’ll connect you with the right Obesity Specialist
Why Obesity Programs Demand Specialized Support
We unite selected obesity sites, a governance model built for rapid decisions, and bias-aware engagement practices to accelerate enrollment, improve retention, and help our partners deliver against critical development timelines.
GLP-1 exposure, growing post-plateau populations, and evolving eligibility criteria have fundamentally changed the obesity treatment landscape. Enrollment assumptions that were reliable just a few years ago no longer accurately reflect today’s patient population.
Emerging obesity innovators run on investor timelines where Phase II readouts drive funding rounds and licensing events. Feasibility is expected in weeks and interim pivots in days.
Individual sites set the tone for participant retention. Bias awareness, patient centric language and size-appropriate equipment decide whether participants come back for their next visit.

Partnership & Approach
Senior scientific and operational leaders engage on obesity programs from kickoff and stay through final data, and our structure is flat enough that protocol amendments and interim analysis pivots are resolved at the team level in days rather than through layers of approval.
Forty obesity studies since 2023, from first-in-human through Phase IV, including rare obesity indications and pediatric populations.
Obesity Studies Since Q1 2023
18 Phase I, 15 Phase II, 5 Phase III and 2 Phase IV, spanning obesity, rare obesity indications including hypothalamic obesity, Bardet-Biedl syndrome, Prader-Willi syndrome, and pediatric populations.

Setting Enrollment Benchmarks;
Faster Than Plan
A Phase IIa GLP-1 RA program enrolled 40% ahead of plan, with the same team staying through final data.

Why Worldwide for Obesity Trials
360+ alliance sites across 26 U.S. states and 42 alliance site groups supporting metabolic studies, within a 2,000+ site metabolic network across 70+ countries, each selected for DEXA access, GLP-1 experience and bias-trained teams.
Strategic site selection, targeted patient identification, and patient-centered support help address competitive recruitment, long-term participation, and consistent endpoint capture in obesity studies.
Experience across GLP-1 RA, NuSH, and combination mechanisms, drawn from more than 14,000 patients in obesity and metabolic programs, with obesity bias mitigation built into site engagement from selection forward.
Frequently Asked Questions
We have answered the questions sponsors ask most often about obesity clinical development. If yours isn’t here, our metabolic team is happy to help.
The widespread adoption of GLP-1 therapies has reshaped obesity populations, making historical recruitment assumptions less reliable. Worldwide addresses this shift by partnering with sites that maintain longitudinal visibility into weight-management populations, including GLP-1 treatment history, weight-loss plateau experiences, discontinuation patterns, and eligibility status. We build these insights into protocol planning early, so inclusion and exclusion criteria reflect the current picture, and recruitment is tailored through targeted prescreening, patient re-engagement, and site-level enrollment strategies.
Worldwide is structured to support the rapid decision-making required in obesity programs where interim data may drive funding milestones, portfolio decisions, or development strategy adjustments. Senior scientific, medical, biostatistical, and operational leaders are actively engaged from study startup, enabling protocol amendments, interim analysis reviews, cohort expansions, and design refinements to be evaluated and implemented quickly without lengthy escalation pathways. This streamlined governance model allows critical program decisions to be made in days rather than weeks.
Worldwide has extensive experience delivering large-scale obesity and cardiometabolic programs. Our track record includes a Phase III GLP-1 receptor agonist program spanning more than 200 sites and approximately 3,500 patients, and a Phase IV cardiovascular outcomes trial enrolling over 12,000 patients across 473 sites in eight countries. This experience gives us deep operational expertise, enabling us to execute obesity programs from early-phase proof-of-concept through global registrational and outcomes trials.
Worldwide’s obesity bias mitigation framework is embedded throughout the study lifecycle, from site selection through enrollment and retention. Sites complete bias awareness training before engaging with participants, use people-first language, and provide size-appropriate equipment and facilities to foster dignity and trust. Worldwide maps the participant journey to identify logistical, financial, and psychosocial barriers, then designs recruitment and retention strategies, such as tailored reimbursement, flexible engagement models, and participant education, to minimize them.
This is way too long for an FAQ section, please try a shortened version: Worldwide maintains data integrity during rapid enrollment through a risk-based quality management approach combining intensified monitoring, real-time centralized data review, and scalable IRT and EDC technology. Dedicated data management, biostatistics, and medical teams coordinate closely to resolve queries quickly without slowing enrollment. This approach is proven at scale, including a Phase IV cardiovascular outcomes trial where Worldwide managed approximately 1.8 million eCRF pages and delivered database lock on schedule.
Can we replace with a shortened version: Worldwide’s obesity, hepatology, and cardiovascular experts operate within a single integrated Cardiovascular & Metabolic team, enabling cross-functional collaboration from protocol design through execution. For obesity-to-MASH programs, metabolic and liver specialists jointly optimize trial design, patient selection, biomarker strategies, and GLP-1-based therapy considerations. For programs with cardiovascular outcomes, obesity and cardiovascular experts align on risk-factor enrichment, endpoint selection, and adjudication requirements, helping sponsors navigate cross-organ development and leverage overlapping patient populations efficiently.
Worldwide combines specialized rare disease operational expertise with established networks of investigators, advocacy organizations, and referral centers to identify and manage small, geographically dispersed populations. Our track record includes a global Phase III hypothalamic obesity program across 33 sites in 8 countries, plus development experience in Prader-Willi, Bardet-Biedl, and other rare metabolic and endocrine disorders. We also bring experience in pediatric and adolescent obesity studies. Together, this enables targeted site selection, advocacy-driven recruitment, caregiver-centric retention, and adaptive trial designs that maximize learning from limited patient populations.